[Chemoprotectors. Mechanisms of action and clinical applications].
Toxicity of chemotherapy remains an important point in the care of patients with malignancies. Since a few years, new compounds without any intrinsic anti tumoral activity have been developed to decrease the toxicity or to enhance the activity of anti-cancer drugs. From those used against the toxic activity of anti-cancer drugs, two classes could be isolated: the chemoprotectors that interact through a specific of chemotherapy in normal cells, and the chemocorrectors that enhance the spontaneous recovery after exposition to cytotoxic drugs. The most widely used chemoprotector remains the 2-mercaptoethanesulfonate (mesna) which protects against the bladder toxicity of ifosfamide and cyclophosphamide. However, two new drugs, amifostine and dextrazoxane have been recently or will be approved in France against the toxicity of cisplatin and anthracyclines, respectively. Mechanism of action and clinical applications of these new drugs in cancer chemotherapy are reviewed.
Raymond
E
E
Service de médecine interne-oncologie, hôpital Saint-Antoine, Paris, France.
D004999:Amifostine / Q000494:pharmacology; D018890:Chemoprevention; D004336:Drug Antagonism; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D015080:Mesna / Q000494:pharmacology* / Q000627:therapeutic use
D004999:Amifostine; D015080:Mesna
Les médicaments chimioprotecteurs. Mécanismes d'action et applications cliniques.